Randomized trial · people
Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trial
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, retatrutide cut liver fat sharply within 24 weeks in people with fatty liver disease, with larger cuts in the higher-dose arms.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 98
- Published
- 2024
- Journal
- Nat Med
What they tested
The team tested how much retatrutide changed liver fat after 24 weeks in people with fatty liver disease, compared with placebo.
How the study was done
A randomized, double-blind, placebo-controlled phase 2a substudy of 98 people from a larger obesity trial who had MASLD (metabolic dysfunction-associated steatotic liver disease, a fatty liver disease) and liver fat of at least 10%. They got weekly injections under the skin of retatrutide (1, 4, 8 or 12 mg) or placebo (a dummy shot) for 48 weeks, with the main result at 24 weeks.

Model. Individual results vary.
What they found
At 24 weeks, average liver fat changed by -42.9% in the 1 mg arm, -57.0% in the 4 mg arm, -81.4% in the 8 mg arm and -82.4% in the 12 mg arm, against +0.3% on placebo (all P < 0.001 versus placebo). Liver fat dropped into the normal range (under 5%) for 27%, 52%, 79% and 86% of people in those arms, and for 0% on placebo. Bigger drops in liver fat went along with changes in body weight, belly fat, and metabolic measures linked to better insulin sensitivity and fat handling.
What it doesn’t show
This is a substudy of a larger obesity trial with 98 people, and its main result comes at 24 weeks. It measured liver fat, not longer-term liver health outcomes.
The paper
Sanyal et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeksRandomized trial · people · 2022
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.